Auron Therapeutics, Inc.

Auron Therapeutics is a privately held patient-centered, platform-powered, product-driven oncology company. We are the leaders in identifying and targeting cell state to treat a range of solid tumors and hematological malignancies.

https://aurontx.com/

11-50 employees

Growth Trajectory

Auron Therapeutics has significant growth potential by expanding its pipeline programs based on the AURIGIN™ platform, developing new targeted cancer therapies, and expanding into new indications, such as autoimmune diseases, while also advancing clinical trials for AUTX-703 and securing further partnerships and investments. The company's innovation in cell-state plasticity and AI-driven drug discovery positions them well for future market expansion and technology advancement.

Technical Challenges

Identifying and validating novel therapeutic targets in oncology.

Developing effective AI/ML approaches to understand and target cellular plasticity.

Integrating multi-omic data and computational models.

Advancing AUTX-703 through clinical trials and demonstrating efficacy.

Tech Stack

AIMachine LearningSingle-cell genomicsKAT2A/B protein degradation technologyMulti-omic profilingComputational biology

Team Size

Medical Director/Senior Medical Director

Executive Leadership (CEO, CFO, CSO)

Clinical Development Team

Data Science Team

Pharmaceutical Sciences Team

Scientific Advisory Board

Key Risks

Competition from other biotechnology and pharmaceutical companies developing cancer therapies.

Challenges in clinical trials and regulatory approvals for new cancer therapies.

Dependence on the AURIGIN™ platform for successful drug discovery and target identification.

Potential for technical hurdles in developing effective AI/ML approaches to understand and target cellular plasticity.

Market challenges in treating aggressive, metastatic, and drug-resistant tumors.

Opportunities

Leveraging the AURIGIN™ platform to identify novel drug targets and biomarkers for personalized therapies.

Expanding the pipeline to include additional solid tumor cancers, hematological malignancies, and inflammatory diseases.

Forming partnerships with pharmaceutical companies and research institutions to accelerate drug development and expand market reach.

Advancing research in cell-state plasticity and targeted therapies to address unmet needs in cancer treatment.

Expanding into autoimmune disease indications by leveraging the AURIGIN™ platform's capabilities.

Live Data Stream

Access Our Live VC Funding Database

30,000+ funded startups

tracked in the last 3 months

B2B verified emails

of key decision makers

Growth metrics

Real-time company performance data

Live updates

of new VC funding rounds

Advanced filters

for sophisticated queries

API access

with multiple export formats

Access Database

Updated every 5 minutes